Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

December Sees Three Milestones For ViiV’s Pipeline

R&D Chief Outlines 2 FDA Filings, 1 Expected Approval

Executive Summary

ViiV Healthcare’s R&D head Kimberly Smith tells Scrip December will see the advancement of three key HIV therapies.

You may also be interested in...



ViiV Seeks Speedy EMA Review For Last-Resort HIV Drug

ViiV Healthcare has asked the European Medicines Agency to accelerate its review of fostemsavir when the company files for pan-EU market approval of the product.

Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers

Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.

Antifungal Specialist F2G Gets Near $61m Financing

A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel